C4 Therapeutics
C4 is building on the knowledge with synthetic chemical compounds.
Market cap
$101m
Enterprise value
($50m)
Share price
$1.43 CCCC
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
EG Capital Group(exited)
Cormorant Asset Management(exited)
Novartis(exited)
Cobro Ventures(exited)
Perceptive Advisors(exited)
Adage Capital(exited)
Axil Capital(exited)
Commodore Capital(exited)
Lightchain Capital(exited)
Logos Capital(exited)
Nextech Invest(exited)
RA Capital Management(exited)
RTW Investments(exited)
Sphera Funds Management(exited)
Taiwania Capital(exited)
Yonjin Venture(exited)
Janus Henderson Investors(exited)
T. Rowe Price(exited)
HBM Partners(exited)
Bain Capital Life Sciences(exited)
Lightchain-capital(exited)
3E Bioventures(exited)
Bain Capital(exited)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 55 % | 38 % | (32 %) | (33 %) | 71 % | (37 %) | (6 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (176 %) | (175 %) | (405 %) | (614 %) | (284 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (200 %) | (183 %) | (412 %) | (638 %) | (296 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 236 % | 207 % | 379 % | 567 % | 311 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.